The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pediatric surgery international (Print)

• Publication date

  2013-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00383-012-3239-7PMID 23274701PMCID PMC3557462
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lancet Oncol 10

  2013cited by this paper
• Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice

  2012cited by this paper
• Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

  2012cited by this paper
• A New Module in Neural Differentiation Control: Two MicroRNAs Upregulated by Retinoic Acid, miR-9 and -103, Target the Differentiation Inhibitor ID2

  2012cited by this paper
• MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway.

  2012cited by this paper
• ALKoma: a cancer subtype with a shared target.

  2012cited by this paper
• EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.

  2012cited by this paper
• MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome

  2012cited by this paper
• High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.

  2012cited by this paper
• Mechanisms of CHD5 Inactivation in Neuroblastomas

  2012cited by this paper
• Dickkopf‐3 is regulated by the MYCN‐induced miR‐17‐92 cluster in neuroblastoma

  2012cited by this paper
• Modulation of Neuroblastoma Disease Pathogenesis By An Extensive Network of Epigenetically Regulated MicroRNAs

  2012cited by this paper
• MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome

  2012cited by this paper
• LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression

  2012influential reference
• Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD2 Coated Nanoparticles

  2012cited by this paper
• Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma

  2012cited by this paper
• Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

  2012influential reference
• Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification

  2012cited by this paper
• microRNA-9 Targets Matrix Metalloproteinase 14 to Inhibit Invasion, Metastasis, and Angiogenesis of Neuroblastoma Cells

  2012cited by this paper
• Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease

  2011cited by this paper
• Tumor suppressor p53 meets microRNAs.

  2011cited by this paper
• MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2

  2011cited by this paper
• MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma.

  2011cited by this paper
• MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival

  2011cited by this paper
• MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma

  2011cited by this paper
• Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci

  2011cited by this paper
• Epigenetic regulation of microRNAs in cancer: an integrated review of literature.

  2011cited by this paper
• MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.

  2011cited by this paper
• Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma

  2011cited by this paper
• CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells.

  2011cited by this paper
• A 6-gene signature identifies four molecular subgroups of neuroblastoma

  2011cited by this paper
• A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.

  2011cited by this paper
• LIN28B promotes colon cancer progression and metastasis.

  2011cited by this paper
• Silencing of miR‐124 induces neuroblastoma SK‐N‐SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR

  2011cited by this paper
• Germline gain‐of‐function mutations of ALK disrupt central nervous system development

  2011cited by this paper
• Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development

  2011cited by this paper
• Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways

  2011cited by this paper
• CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression

  2011cited by this paper
• Integrative genomics identifies LMO1 as a neuroblastoma oncogene

  2011cited by this paper
• Genome-Wide Linkage Analysis to Identify Genetic Modifiers of ALK Mutation Penetrance in Familial Neuroblastoma

  2011cited by this paper
• Emerging importance of ALK in neuroblastoma.

  2011cited by this paper
• Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms.

  2011cited by this paper
• Neuroblastoma epigenetics: From candidate gene approaches to genome-wide screenings

  2011cited by this paper
• The Role of miR-103 and miR-107 in Regulation of CDK5R1 Expression and in Cellular Migration

  2011cited by this paper
• High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma

  2011cited by this paper
• ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome

  2011cited by this paper
• MiR-27b targets PPARγ to inhibit growth, tumor progression, and the inflammatory response in neuroblastoma cells

  2011cited by this paper
• p53 is a direct transcriptional target of MYCN in neuroblastoma.

  2010cited by this paper
• Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis

  2010cited by this paper
• High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

  2010cited by this paper
• MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells.

  2010cited by this paper
• MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors

  2010cited by this paper
• High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset

  2010cited by this paper
• miR‐149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells

  2010cited by this paper
• Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q− Neuroblastoma

  2010cited by this paper
• The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma.

  2010cited by this paper
• Accurate prediction of neuroblastoma outcome based on miRNA expression profiles

  2010cited by this paper
• MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation.

  2010cited by this paper
• Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q

  2010cited by this paper
• MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.

  2010cited by this paper
• MYCN-regulated microRNAs repress estrogen receptor-α (ESR1) expression and neuronal differentiation in human neuroblastoma

  2010cited by this paper
• miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro.

  2010cited by this paper
• Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature

  2010cited by this paper
• An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours

  2010cited by this paper
• Global genomic and RNA profiles for novel risk stratification of neuroblastoma

  2010cited by this paper
• MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2

  2010cited by this paper
• MicroRNAs-10a and -10b Contribute to Retinoic Acid-induced Differentiation of Neuroblastoma Cells and Target the Alternative Splicing Regulatory Factor SFRS1 (SF2/ASF)*

  2010cited by this paper
• Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

  2009cited by this paper
• Features of Mammalian microRNA Promoters Emerge from Polymerase II Chromatin Immunoprecipitation Data

  2009cited by this paper
• MicroRNA-125b Promotes Neuronal Differentiation in Human Cells by Repressing Multiple Targets

  2009cited by this paper
• Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.

  2009cited by this paper
• Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation.

  2009cited by this paper
• MicroRNA-125b is a novel negative regulator of p53.

  2009cited by this paper
• Lin28 Enhances Tumorigenesis and is Associated With Advanced Human Malignancies

  2009cited by this paper
• LIN-28 and the poly(U) polymerase PUP-2 regulate let-7 microRNA processing in Caenorhabditis elegans

  2009cited by this paper
• Widespread Dysregulation of MiRNAs by MYCN Amplification and Chromosomal Imbalances in Neuroblastoma: Association of miRNA Expression with Survival

  2009influential reference
• MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes

  2009cited by this paper
• Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in embryonic stem cells

  2009cited by this paper
• Global MYCN Transcription Factor Binding Analysis in Neuroblastoma Reveals Association with Distinct E-Box Motifs and Regions of DNA Hypermethylation

  2009cited by this paper
• p53 represses c-Myc through induction of the tumor suppressor miR-145

  2009cited by this paper
• An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation.

  2009cited by this paper
• TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation.

  2009cited by this paper
• MiR‐128 up‐regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness

  2009cited by this paper
• Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.

  2009cited by this paper
• The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

  2009cited by this paper
• Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma

  2009cited by this paper
• Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.

  2009cited by this paper
• MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.

  2009cited by this paper
• High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma.

  2009cited by this paper
• A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation

  2008cited by this paper
• CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas

  2008cited by this paper
• A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene

  2008cited by this paper
• Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma

  2008cited by this paper
• Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIM

  2008cited by this paper
• High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene

  2008cited by this paper
• Methylation of tumor‐suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors

  2008cited by this paper
• p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.

  2008cited by this paper
• Subclassification and Individual Survival Time Prediction from Gene Expression Data of Neuroblastoma Patients by Using CASPAR

  2008cited by this paper
• Downregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrest

  2008cited by this paper
• Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.

  2008cited by this paper

• PP2A activation targets MYCN in neuroblastoma

  2026cites this paper
• Microbiome in Neuroblastoma: A Virgin Island in the World of Onco-Microbiome

  2025cites this paper
• Prediction of Composite Clinical Outcomes for Childhood Neuroblastoma Using Multi-Omics Data and Machine Learning

  2024cites this paper
• In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma

  2024cites this paper
• Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion

  2023cites this paper
• Neuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targets.

  2023cites this paper
• Epigenetic Dysregulation in MYCN-Amplified Neuroblastoma

  2023cites this paper
• Characterization of m6A-related lncRNA signature in neuroblastoma

  2022cites this paper
• Elucidating miRNA Function in Cancer Biology via the Molecular Genetics’ Toolbox

  2022cites this paper
• bub1 as a potential oncogene and a prognostic biomarker for neuroblastoma

  2022cites this paper
• A Chemo-Genomic Approach Identifies Diverse Epigenetic Therapeutic Vulnerabilities in MYCN-Amplified Neuroblastoma

  2021cites this paper
• Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma

  2021cites this paper
• Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs

  2021cites this paper
• Crosstalk of the Wnt/β-Catenin Signaling Pathway in the Induction of Apoptosis on Cancer Cells

  2021cites this paper
• Prognostic Signature of Immune Genes and Immune-Related LncRNAs in Neuroblastoma: A Study Based on GEO and TARGET Datasets

  2021cites this paper
• The emerging role of non-coding RNAs in the epigenetic regulation of pediatric cancers.

  2021cites this paper
• Non-Genomic Control of Dynamic MYCN Gene Expression in Liver Cancer

  2021cites this paper
• Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma

  2020cites this paper
• Association of RASSF1A, DCR2, and CASP8 Methylation with Survival in Neuroblastoma: A Pooled Analysis Using Reconstructed Individual Patient Data

  2020cites this paper
• Downregulated NORAD in neuroblastoma promotes cell proliferation via chromosomal instability and predicts poor prognosis.

  2020cites this paper
• Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action

  2020cites this paper
• A Context-Dependent Role for MiR-124-3p on Cell Phenotype, Viability and Chemosensitivity in Neuroblastoma in vitro

  2020cites this paper
• NBPF1 independently determine the risk stratification and prognosis of patients with neuroblastoma.

  2020cites this paper
• Integrative Omic Analysis of Neuroblastoma

  2019cites this paper
• The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.

  2019cites this paper
• The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development

  2019cites this paper
• RNA sequencing reveals a key role for the long non-coding RNA MIAT in regulating neuroblastoma and glioblastoma cell fate.

  2019cites this paper
• Chronic Persistent Neuroblastoma, a Unique Presentation and Clinical Course in a Six-Year-Old Child: A Case Report

  2019cites this paper
• Role of Genetic and Epigenetic Alterations in Pathogenesis of Neuroblastoma

  2019cites this paper
• Genetic markers in neuroblastoma

  2019cites this paper
• Overexpression of CAMK 2 N 1 indicates good prognosis for glioma and regulates androgen receptor-associated cell proliferation and apoptosis

  2019cites this paper
• Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification

  2019cites this paper
• Neuroblastoma

  2018cites this paper
• A physiologically relevant 3D collagen-based scaffold-neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models.

  2018cites this paper
• Identification of Potential Prognostic Genes for Neuroblastoma

  2018cites this paper
• Nouvelle thérapie épigénétique dans le traitement du neuroblastome pédiatrique

  2018cites this paper
• A review of neuroblastoma: prevalence, diagnosis, related genetic factors, and treatment

  2018influential citation
• Identification of a MYCN and Wnt-related VANGL2-ITLN1 fusion gene in neuroblastoma

  2018cites this paper
• Nanotecnología, nanomedicina, cáncer y diabetes

  2018cites this paper
• MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma

  2017cites this paper
• miR-506 suppresses neuroblastoma metastasis by targeting ROCK1.

  2017cites this paper
• Dinutuximab in the Treatment of High-Risk Neuroblastoma in Children

  2017cites this paper
• Microarray expression analysis of MYCN-amplified neuroblastoma cells after inhibition of CDK2.

  2017cites this paper
• Results of neuroblastoma treatment in Lithuania: a single centre experience

  2017cites this paper
• Artemether Regulates Chemosensitivity to Doxorubicin via Regulation of B7-H3 in Human Neuroblastoma Cells

  2017cites this paper
• Promoter hypermethylation as a mechanism for Lamin A/C silencing in a subset of neuroblastoma cells

  2017cites this paper
• Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance

  2017cites this paper
• Tobacco, alcohol and illicit drugs during pregnancy and risk of neuroblastoma: systematic review

  2017cites this paper
• N-Myc Inhibition: Advances in Neuroblastoma Treatment

  2017cites this paper
• A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma

  2017cites this paper
• The effects of selective inhibitors of N-Glycosylation and Endoplasmic Reticulum stress inducers on Neuroblastoma cell proliferation and Apoptosis

  2017cites this paper
• Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma

  2016cites this paper
• Neuroblastoma: A Tough Nut to Crack.

  2016cites this paper
• The Role of Intracellular Calcium for the Development and Treatment of Neuroblastoma

  2015cites this paper
• Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma

  2015cites this paper
• Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.

  2015cites this paper
• Frequency of the ALK gene and its prognostic value in neuroblastoma by FISH

  2015cites this paper
• MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown

  2015cites this paper
• DNA Copy Number Changes and Beyond

  2015cites this paper
• Forkheads in neuroblastoma & human longevity: From the womb to the tomb

  2015cites this paper
• Chapter 13 – Neuroblastoma

  2015cites this paper
• MRP1 and its role in anticancer drug resistance

  2015cites this paper
• Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma

  2015influential citation
• Measuring Transcription Rate Changes via Time-Course 4-Thiouridine Pulse-Labelling Improves Transcriptional Target Identification.

  2015cites this paper
• Cancer Biology and Signal Transduction GSK 3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms , Including p 53 and Wnt Signaling

  2014cites this paper
• MicroRNA-29b regulates TGF-β1-mediated epithelial-mesenchymal transition of retinal pigment epithelial cells by targeting AKT2.

  2014cites this paper
• GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms including p53 and Wnt signalling Running title: GSK3 Inhibitors, Potential Neuroblastoma Therapeutic Agents

  2013cites this paper
• GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling

  2013cites this paper